-
Poly(A) Tails: A Critical Quality Attribute in mRNA-based Therapeutics
Wed Sep 06 11:13:08 CST 2023
mRNA has now entered the main stage of therapeutic development and commercialization for multiple indications. The poly(A) tail is central to mRNA translatability, stability, and ultimately, therapeutic benefit. -
FDA Approves First Biosimilar to Treat Multiple Sclerosis
Tue Aug 29 10:20:42 CST 2023
August 24, 2023, The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).
Send Inquiry